04:40 PM EDT, 08/12/2025 (MT Newswires) -- Mineralys Therapeutics ( MLYS ) reported a Q2 GAAP loss late Tuesday of $0.66 per diluted share, narrowing from a loss of $0.83 a year earlier.

Analysts polled by FactSet expected a loss of $0.74.

As of June 30, the company had cash, cash equivalents and investments of $324.9 million.

The company said its cash reserves can fund clinical trials, regulatory activities and corporate operations into 2027.